Literature DB >> 20472887

Tissue slice grafts: an in vivo model of human prostate androgen signaling.

Hongjuan Zhao1, Rosalie Nolley, Zuxiong Chen, Donna M Peehl.   

Abstract

We developed a tissue slice graft (TSG) model by implanting thin, precision-cut tissue slices derived from fresh primary prostatic adenocarcinomas under the renal capsule of immunodeficient mice. This new in vivo model not only allows analysis of approximately all of the cell types present in prostate cancer within an intact tissue microenvironment, but also provides a more accurate assessment of the effects of interventions when tissues from the same specimen with similar cell composition and histology are used as control and experimental samples. The thinness of the slices ensures that sufficient samples can be obtained for large experiments as well as permits optimal exchange of nutrients, oxygen, and drugs between the grafted tissue and the host. Both benign and cancer tissues displayed characteristic histology and expression of cell-type specific markers for up to 3 months. Moreover, androgen-regulated protein expression diminished in TSGs after androgen ablation of the host and was restored after androgen repletion. Finally, many normal secretory epithelial cells and cancer cells in TSGs remained viable 2 months after androgen ablation, consistent with similar observations in postprostatectomy specimens following neoadjuvant androgen ablation. Among these were putative Nkx3.1(+) stem cells. Our novel TSG model has the appropriate characteristics to serve as a useful tool to model all stages of disease, including normal tissue, premalignant lesions, well-differentiated cancer, and poorly differentiated cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20472887      PMCID: PMC2893666          DOI: 10.2353/ajpath.2010.090821

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  45 in total

1.  Evidence of pluripotent human prostate stem cells in a human prostate primary xenograft model.

Authors:  Wendy J Huss; Danny R Gray; Eric S Werdin; William K Funkhouser; Gary J Smith
Journal:  Prostate       Date:  2004-07-01       Impact factor: 4.104

2.  Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.

Authors:  S S Chang; V E Reuter; W D Heston; B Hutchinson; L S Grauer; P B Gaudin
Journal:  Cancer       Date:  2000-01-15       Impact factor: 6.860

3.  Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease.

Authors:  Michael J Donovan; Iman Osman; Faisal M Khan; Yevgen Vengrenyuk; Paola Capodieci; Michael Koscuiszka; Aseem Anand; Carlos Cordon-Cardo; Jose Costa; Howard I Scher
Journal:  BJU Int       Date:  2009-07-14       Impact factor: 5.588

4.  The androgen axis in recurrent prostate cancer.

Authors:  James L Mohler; Christopher W Gregory; O Harris Ford; Desok Kim; Catharina M Weaver; Peter Petrusz; Elizabeth M Wilson; Frank S French
Journal:  Clin Cancer Res       Date:  2004-01-15       Impact factor: 12.531

5.  Quantitation of apoptotic activity following castration in human prostatic tissue in vivo.

Authors:  Andrea Staack; Adrienne P Kassis; Adam Olshen; Yuzhuo Wang; David Wu; Peter R Carroll; Gary D Grossfeld; Gerald R Cunha; Simon W Hayward
Journal:  Prostate       Date:  2003-02-15       Impact factor: 4.104

6.  Short-term human prostate primary xenografts: an in vivo model of human prostate cancer vasculature and angiogenesis.

Authors:  Danny R Gray; Wendy J Huss; Jeffrey M Yau; Lori E Durham; Eric S Werdin; William K Funkhouser; Gary J Smith
Journal:  Cancer Res       Date:  2004-03-01       Impact factor: 12.701

7.  Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate.

Authors:  Li Zeng; Randall G Rowland; Subodh M Lele; Natasha Kyprianou
Journal:  Hum Pathol       Date:  2004-03       Impact factor: 3.466

8.  Effect of castration and testosterone propionate on mouse vibrissae.

Authors:  L Ibrahim; E A Wright
Journal:  Br J Dermatol       Date:  1983-03       Impact factor: 9.302

Review 9.  Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee.

Authors:  Scott B Shappell; George V Thomas; Richard L Roberts; Ron Herbert; Michael M Ittmann; Mark A Rubin; Peter A Humphrey; John P Sundberg; Nora Rozengurt; Roberto Barrios; Jerrold M Ward; Robert D Cardiff
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

10.  A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice.

Authors:  Rozemarijn S van Rijn; Elles R Simonetti; Anton Hagenbeek; Marieke C H Hogenes; Roel A de Weger; Marijke R Canninga-van Dijk; Kees Weijer; Hergen Spits; Gert Storm; Louis van Bloois; Ger Rijkers; Anton C M Martens; Saskia B Ebeling
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113

View more
  31 in total

1.  Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer.

Authors:  Junqiang Tian; Hongjuan Zhao; Rosalie Nolley; Stephen W Reese; Sarah R Young; Xuejun Li; Donna M Peehl; Susan J Knox
Journal:  Clin Cancer Res       Date:  2012-04-25       Impact factor: 12.531

2.  Development of a realistic in vivo bone metastasis model of human renal cell carcinoma.

Authors:  Maija P Valta; Hongjuan Zhao; Alexandre Ingels; Alan E Thong; Rosalie Nolley; Matthias Saar; Donna M Peehl
Journal:  Clin Exp Metastasis       Date:  2014-04-09       Impact factor: 5.150

Review 3.  Patient-Derived Prostate Cancer: from Basic Science to the Clinic.

Authors:  Gail P Risbridger; Renea A Taylor
Journal:  Horm Cancer       Date:  2016-05-13       Impact factor: 3.869

4.  Estrogen-initiated transformation of prostate epithelium derived from normal human prostate stem-progenitor cells.

Authors:  Wen-Yang Hu; Guang-Bin Shi; Hung-Ming Lam; Dan-Ping Hu; Shuk-Mei Ho; Ikenna C Madueke; Andre Kajdacsy-Balla; Gail S Prins
Journal:  Endocrinology       Date:  2011-03-22       Impact factor: 4.736

Review 5.  Development of patient-derived xenograft models of prostate cancer for maintaining tumor heterogeneity.

Authors:  Changhong Shi; Xue Chen; Dengxu Tan
Journal:  Transl Androl Urol       Date:  2019-10

6.  Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance.

Authors:  Hung-Ming Lam; Holly M Nguyen; Eva Corey
Journal:  Methods Mol Biol       Date:  2018

7.  To target or not to target the enemy within localized prostate cancer.

Authors:  Gail Risbridger; Renea Taylor
Journal:  Cell Cycle       Date:  2013-09-23       Impact factor: 4.534

8.  Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor.

Authors:  Kayvan R Keshari; Renuka Sriram; Mark Van Criekinge; David M Wilson; Zhen J Wang; Daniel B Vigneron; Donna M Peehl; John Kurhanewicz
Journal:  Prostate       Date:  2013-03-26       Impact factor: 4.104

9.  Tissue slice grafts of human renal cell carcinoma: an authentic preclinical model with high engraftment rate and metastatic potential.

Authors:  Alan E Thong; Hongjuan Zhao; Alexandre Ingels; Maija P Valta; Rosalie Nolley; Jennifer Santos; Sarah R Young; Donna M Peehl
Journal:  Urol Oncol       Date:  2013-08-02       Impact factor: 3.498

Review 10.  Imaging preclinical tumour models: improving translational power.

Authors:  Marion de Jong; Jeroen Essers; Wytske M van Weerden
Journal:  Nat Rev Cancer       Date:  2014-06-19       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.